|
|
(13 intermediate revisions not shown.) |
Line 1: |
Line 1: |
- | The pathways on this portal are grouped in the following categories: SARS-CoV-2 Pathways, Other coronaviruses (e.g. MERS, SARS-CoV) and virus-host specific interactions (e.g. ACE2).
| + | === Pathway Collection === |
| + | All pathways tagged with "Curation: COVID-19" will be linked to this [https://www.wikipathways.org/index.php?title=Special:CurationTags&showPathwaysFor=Curation%3ACOVID19 overview table], to help keep track of the relevant pathways. |
| | | |
- | {| class="wikitable sortable" style="float:left; margin-left: 10px;"
| + | Download all human [https://www.wikipathways.org//wpi/batchDownload.php?species=Homo%20sapiens&fileType=gpml&tag=Curation:COVID19 COVID19 pathways] |
- | ! Title || Links WP || Category || Status
| + | |
- | |-
| + | |
- | | SARS-CoV-2 and COVID-19 Pathway || [https://www.wikipathways.org/index.php/Pathway:WP4846 WP4846] || SARS-CoV-2 Pathways || style="font-style: italic; color: blue;" | Approved
| + | |
- | |-
| + | |
- | | Hijack of Ubiquitination by SARS-CoV-2 || [https://www.wikipathways.org/index.php/Pathway:WP4860 WP4860] || SARS-CoV-2 Pathways || style="font-style: italic; color: blue;" | Approved
| + | |
- | |-
| + | |
- | | Type I Interferon Induction and Signaling During SARS-CoV-2 Infection || [https://www.wikipathways.org/index.php/Pathway:WP4868 WP4868] || SARS-CoV-2 Pathways || style="font-style: italic; color: orange;" | In Progress
| + | |
- | |-
| + | |
- | | COVID-19, thrombosis and anticoagulation || [https://www.wikipathways.org/index.php/Pathway:WP4927 WP4927] || SARS-CoV-2 Pathways || style="font-style: italic; color: orange;" | In Progress
| + | |
- | |-
| + | |
- | | Activation of NLRP3 Inflammasome by SARS-CoV-2 || [https://www.wikipathways.org/index.php/Pathway:WP4876 WP4876] || SARS-CoV-2 Pathways || style="font-style: italic; color: orange;" | In Progress
| + | |
- | |-
| + | |
- | | SARS-CoV-2 and Angiotensin-converting enzyme 2 (ACE2) receptor: <br/> Molecular mechanisms and potential therapeutic target || [https://www.wikipathways.org/index.php/Pathway:WP4883 WP4883] || SARS-CoV-2 Pathways || style="font-style: italic; color: orange;" | In Progress
| + | |
- | |-
| + | |
- | | COVID-19 AOP || [https://www.wikipathways.org/index.php/Pathway:WP4891 WP4891] || SARS-CoV-2 Pathways || style="font-style: italic; color: orange;" | In Progress
| + | |
- | |-
| + | |
- | | nsp9/nsp10-mediated SARS-CoV-2 pathogenesis || [https://www.wikipathways.org/index.php/Pathway:WP4884 WP4884] || SARS-CoV-2 Pathways || style="font-style: italic; color: orange;" | In Progress
| + | |
- | |-
| + | |
- | | LDLRAD4 pathway in COVID-19 || [https://www.wikipathways.org/index.php/Pathway:WP4904 WP4904] || SARS-CoV-2 Pathways || style="font-style: italic; color: orange;" | In Progress
| + | |
- | |-
| + | |
- | | Overview of perturbations to host-cell autophagy,<br/> induced by distinct proteins of SARS-CoV-2 || [https://www.wikipathways.org/index.php/Pathway:WP4936 WP4936] || SARS-CoV-2 Pathways || style="font-style: italic; color: orange;" | In Progress
| + | |
- | |-
| + | |
| | | |
- | | Coronavirus lipid metabolism || [https://www.wikipathways.org/index.php/Pathway:WP4853 WP4853] || Other coronaviruses || style="font-style: italic; color: orange;" | In Progress
| + | === Contact us === |
- | |-
| + | Send questions about WikiPathways to the [mailto:wikipathways-discuss@googlegroups.com wikipathways-discuss mailing list]. |
- | | Host-pathogen interaction of human corona viruses - autophagy || [https://www.wikipathways.org/index.php/Pathway:WP4863 WP4863] || Other coronaviruses || style="font-style: italic; color: orange;" | In Progress
| + | |
- | |-
| + | === How to add a pathway to the portal === |
- | | Host-pathogen interaction of human corona viruses - apoptosis || [https://www.wikipathways.org/index.php/Pathway:WP4864 WP4864] || Other coronaviruses || style="font-style: italic; color: orange;" | In Progress
| + | |
- | |-
| + | The list of Featured Pathways is not static and can be updated at any time. If you know of a pathway that should be added, please [mailto:martina.kutmon@maastrichtuniversity.nl contact the administrator]. |
- | | SARS coronavirus and innate immunity || [https://www.wikipathways.org/index.php/Pathway:WP4912 WP4912] || Other coronaviruses || style="font-style: italic; color: orange;" | In Progress
| + | |
- | |-
| + | * See our Help section for [[:Help:New_Contributor_Quickstart|New Contributor QuickStart]], [[:Help:Guidelines_EditorPalette|Editor's Palette Guide]] and [[:Help:Guidelines|Guidelines for Contributors]]. |
- | | ER stress response in Coronavirus infection || [https://www.wikipathways.org/index.php/Pathway:WP4861 WP4861] || Other coronaviruses || style="font-style: italic; color: orange;" | In Progress
| + | |
- | |-
| + | |
- | | Downregulation of ACE2 expression by SARS-CoV <br/>infection and SARS-CoV Spike protein || [https://www.wikipathways.org/index.php/Pathway:WP4799 WP4799] || Other coronaviruses || style="font-style: italic; color: orange;" | In Progress
| + | |
- | |-
| + | |
- | | Host-pathogen interaction of human <br/> corona viruses - MAPK signaling|| [https://www.wikipathways.org/index.php/Pathway:WP4877 WP4877] || Other coronaviruses || style="font-style: italic; color: orange;" | In Progress
| + | |
- | |-
| + | |
- | | Host-pathogen interaction of human <br/> corona viruses - Interferon induction || [https://www.wikipathways.org/index.php/Pathway:WP4880 WP4880] || Other coronaviruses || style="font-style: italic; color: orange;" | In Progress
| + | |
- | |-
| + | |
- | | ACE Inhibitor Pathway|| [https://www.wikipathways.org/index.php/Pathway:WP554 WP554] || ACE2 || style="font-style: italic; color: orange;" | In Progress
| + | |
- | |-
| + | |
- | | Metabolism of Angiotensinogen to Angiotensins (Reactome) || [https://www.wikipathways.org/index.php/Pathway:WP2729 WP2729] || ACE2 || style="font-style: italic; color: orange;" | In Progress
| + | |
- | |-
| + | |
- | |}
| + | |
The list of Featured Pathways is not static and can be updated at any time. If you know of a pathway that should be added, please contact the administrator.